We have developed multifunctional pH-responsive DNMs based on RCA technology for the co-delivery of the anticancer drug Dox and therapeutic gene ALK-specific siRNA, achieving a combination of chemotherapy and gene therapy for ALCL both in vitro and in vivo. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.